Copy Link Print Information

Bevacizumab

(Synonyms: Anti-Human VEGF, Humanized Antibody)
63 Cited Publications
Customer Review

Based on 63 publication(s) in Google Scholar

Bevacizumab (Anti-Human VEGF, Humanized Antibody) is a humanized monoclonal antibody against VEGF-A and an angiogenesis inhibitor. Bevacizumab blocks the interaction between VEGF-A and VEGF receptors. Bevacizumab possesses immunomodulatory properties. Bevacizumab can be used in research on metastatic colorectal cancer, metastatic breast cancer, and non-small cell lung cancer.

For research use only. We do not sell to patients.

  • Purity: 98.90%
  • CAS No.: 216974-75-3
  • Molecular Weight:146.56 kDa
  • Storage:

    Please store the product under the recommended conditions in the Certificate of Analysis.

  • Experimental Validation Results for Bevacizumab
  • Experimental Validation Results for Bevacizumab
  • Experimental Validation Results for Bevacizumab
  • Experimental Validation Results for Bevacizumab
  • Experimental Validation Results for Bevacizumab
  • Experimental Validation Results for Bevacizumab
  • Experimental Validation Results for Bevacizumab
  • Experimental Validation Results for Bevacizumab
  • Experimental Validation Results for Bevacizumab
  • Experimental Validation Results for Bevacizumab
  • Experimental Validation Results for Bevacizumab
  • Experimental Validation Results for Bevacizumab
  • Bevacizumab Chemical Structure
    Bevacizumab Chemical Structure
CAS No.: 216974-75-3
Size
Price
Stock
Quantity
Amount: USD 0.00
Please select quantity
or
or

* Please select Quantity before adding items.

To place orders, for customer services and technical support, please contact: MedChemExpress USA

Tel: 609-228-6898 E-mail: [email protected] [email protected]

Data Download
Other Forms of Bevacizumab:

To place orders, for customer services and technical support, please contact:

609-228-6898
[email protected] [email protected]
Find Your Local Distributor Your local distributor: Hycultec GmbHHycultec
  • Biological Activity
  • Chemical Information
  • Protocol
  • Purity & Documentation
  • References
  • Help & FAQs
Top Publications Citing

Use of MCE Products

Publications Citing Use of MedChemExpress (MCE) Bevacizumab

More
Customer Validation & Images
IHCWBIn Vivo Efficacy StudyCell Migration/Invasion AssayIFOthersFlow Cytometry
  • In Vivo Efficacy Study
  • In Vivo Efficacy Study
  • IHC
  • In Vivo Efficacy Study
  • Flow Cytometry
  • WB
  • IF
  • Cell Migration/Invasion Assay
  • Others

All VEGFR Isoforms

More

Keywords

MOQ
Minimum order quantity
100 mg

Get Quote In-stock

Other size
Get Quote
Please select quantity
Amount: USD 0.00
Sign in to MedChemExpress Sign In
Register
Sign in to MedChemExpress
Register New Account

At least 6 characters

Personalize your experience, you are currently not signed in. For a better experience, please create an online profile, you can:

Obtain points redemption prizes
Check out faster
Add multiple shipping locations
View orders
Assay Types
  • 1/16

    Human IgG1 kappa

  • 1/16

    Flow cytometric analysis of 1X106 Hela cells with Bevacizumab (HY-P9906, red). Cells were fixed with 4% paraformaldehyde and permeabilised with 90% methanol. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. Alexa Fluor 488-conjugated AffiniPure Goat Anti-Human IgG H&L (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG1 kappa (HY-P99001, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).

  • 1/16

    Immobilized VEGF165 Protein, Human (HY-P7110A) can bind Bevacizumab. The EC50 for this effect is 5.34 ng/mL.

  • 1/16

    Bevacizumab purchased from MedChemExpress. Usage Cited in: Signal Transduct Target Ther. 2025 Dec 24;10(1):417. [Abstract]

    Customer Validation
     Treatment of PC9-BM LCN2-high BM-bearing mice with SH4-54 (10 mg/kg, intraperitoneally, twice per week), Bevacizumab (10mg/kg, intraperitoneally, twice per week), or a combination of both significantly suppressed tumor progression and prolonged overall survival.

  • 1/16

    Bevacizumab purchased from MedChemExpress. Usage Cited in: J Clin Oncol. 2025 Mar;43(7):840-851. [Abstract]

    Customer Validation
     Tumor-bearing mice were treated with vehicle, Onvansertib, and/or Bevacizumab (intraperitoneally, 5 mg/kg for SW620 and HCT116, 1 mg/kg for LoVo, twice a week) for 30-33 days.

  • 1/16

    Bevacizumab purchased from MedChemExpress. Usage Cited in: Autophagy. 2025 Mar;21(3):619-638. [Abstract]

    Customer Validation
     VEGFA IHC staining in control and ATL-I (80 μM or 160 μM)-treated Matrigel plugs. Quantification of vegfa-positive cells. Scale bar: 100 μm. In the present set of experiments, Bevacizumab (50 ng/ml) was used as the positive control.

  • 1/16

    Bevacizumab purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Nov 18;16(1):10096. [Abstract]

    Customer Validation
     Atezolizumab (4 mg/kg; i.v.) + Bevacizumab (1 mg/kg; i.v.), every other day for 14 days (G4 group) in PDX subcutaneous mouse model. Collected tumor tissues of mice at the end of treatment in different groups.

  • 1/16

    Bevacizumab purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Nov 18;16(1):10096. [Abstract]

    Customer Validation
     Atezolizumab (4mg/kg; i.v.) + Bevacizumab (1mg/kg; i.v.), every other day for 14 days (G4 group) in PDX subcutaneous mouse model. Flow cytometric analysis of anti-CD68/CD206-stained macrophages (gated on CD45+ cells), anti-CD68/CD80-stained macrophages (gated on CD45+ cells),anti-HLA-DR/CD11c-stained DCs (gated on CD45+ Lin-1- T cells), and anti-CD3/CD8-stained T cells (gated on CD45+ cells) in tumor tissues after different treatments (n = 5 independent mice).

  • 1/16

    Bevacizumab purchased from MedChemExpress. Usage Cited in: Brain Res. 2026 Jan 1:1870:150069. [Abstract]

    Customer Validation
     Bevacizumab (Anti-VEGFA) (HY-P9906) (15 mg/kg; i.p.; once every other day for one week) significantly reversed the upregulatory effect of TQHXD and HXHY on VEGFA protein in MCAO rats.

  • 1/16

    Bevacizumab purchased from MedChemExpress. Usage Cited in: Brain Res. 2026 Jan 1:1870:150069. [Abstract]

    Customer Validation
     Bevacizumab (Anti-VEGFA) (HY-P9906) (15 mg/kg; i.p.; once every other day for one week) effectively antagonized the inherent pro-angiogenic effects of TQHXD and HXHY in MCAO rats.

  • 1/16

    Bevacizumab purchased from MedChemExpress. Usage Cited in: Cancer Res. 2024 Jun 4;84(11):1781-1798. [Abstract]

    Customer Validation
     Transwell assays showing that Bevacizumab (200 ng/mL, 12 h) failed to inhibit the migration of HUVECs treated with recombinant PTN protein. Unpaired t test; **, P < 0.01; ****, P <0.0001.

  • 1/16

    Bevacizumab purchased from MedChemExpress. Usage Cited in: Cancer Res. 2024 Jun 4;84(11):1781-1798. [Abstract]

    Customer Validation
     Tube formation assays showed that Bevacizumab (200 ng/mL) failed to inhibit the tube formation of HUVECs induced by recombinant PTN protein.Unpaired t test; ***, P <0.001; ****, P <0.0001.

  • Bevacizumab Chemical Structure
    1/16
  • Bevacizumab
  • Flow cytometric analysis of 1X106 Hela cells with Bevacizumab (HY-P9906, red). Cells were fixed with 4% paraformaldehyde and permeabilised with 90% methanol. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. Alexa Fluor 488-conjugated AffiniPure Goat Anti-Human IgG H&L (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG1 kappa (HY-P99001, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).
  • Immobilized VEGF165 Protein, Human (HY-P7110A) can bind Bevacizumab. The EC50 for this effect is 5.34 ng/mL.